CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015.
The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy
The contract supports the development of drugs to treat HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as microbicides for preventing
Upon issuance, the U.S. Patent entitled, "Process for Producing a Composition Containing Active Follistatin," will provide intellectual property protection for making the key ingredient in MYOS’ core commercial
Abbott (ABT), the makers of Similac and experts in infant nutrition for nearly 90 years, studied the diets of more than 80 lactating women to assess how their
Zydelig has been approved by The U.S. Food and Drug Administration (FDA) for the treatment of three different B-cell blood cancers: 1. In combination with rituximab for patients
Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States. With this addition, WCG’s biosafety division
KX2-391 is a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization. KX2-391 promotes the induction of p53, G2/M arrest of proliferating
Welichem, Celestial and BWTP have been trying to negotiate with the relevant Chinese authorities since 2012 to obtain approval of the China APA as required for the transfer
The Phase I trial, conducted in the US, was an open-label, single-arm, multicentre study, to assess safety, tolerability, and levels of anti-drug antibodies in the patients’ serum. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.